Reata Pharmaceuticals Inc. Cl A | Mutual Funds
Mutual Funds that own Reata Pharmaceuticals Inc. Cl A
Vanguard Total Stock Market Index Fund
437,069
1.84%
75,600
0.01%
07/31/2018
Fidelity Select Biotechnology Portfolio
353,797
1.49%
82,958
0.33%
07/31/2018
iShares Russell 2000 ETF
332,902
1.4%
-177
0.06%
09/06/2018
Emerald Growth Fund
289,653
1.22%
21,500
1.75%
04/30/2018
iShares Nasdaq Biotechnology ETF
274,526
1.15%
-3,591
0.24%
09/06/2018
Vanguard Extended Market Index Fund
215,495
0.91%
58,431
0.03%
07/31/2018
Candriam Equities L - Biotechnology
192,700
0.81%
53,700
1.23%
07/31/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
174,400
0.74%
0
0.65%
06/30/2018
AST Small Cap Growth Portfolio
169,903
0.72%
-6,716
1.54%
03/29/2018
iShares Russell 2000 Growth ETF
153,460
0.65%
0
0.12%
09/06/2018
| Address |
2801 Gateway Drive
Irving Texas 75063
United States
|
|
Employees
|
- |
| Website |
http://www.reatapharma.com |
| Updated |
07/08/2019 |
| Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. |
